Back
  1. Home
  3. Detailled Reference
Request a copy
Paper published in a journal (Scientific congresses and symposiums)
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
Dieras, V; Jassem, J; Dirix, L.Y. et al.
2011 • In Journal of Clinical Oncology, 29
Peer Reviewed verified by ORBi
Permalink
https://hdl.handle.net/2268/157184
 

Files (1)Send toDetailsStatisticsBibliographySimilar publications

Files

Full Text
AMG 2011.pdf
Publisher postprint (25.15 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to


Details


Disciplines :
Oncology
Author, co-author :
Dieras, V;  Department of Medical Oncology, Institut Curie, Paris, France
Jassem, J;  Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
Dirix, L.Y.;  Sint-Augustinus, Antwerp, Belgium
Guastalla, J.P.;  Centre Léon Bérard, Lyon, France
Bono, P;  Helsinki University Hospital, Helsinki, Finland
Hurvitz, S.A.;  David Geffen School of Medicine at University of California, Los Angeles, CA
Gonçalves, A;  Medical Oncology, Institut Paoli-Calmettes, Marseille, France
Romieu, G;  C.R.L.C. Val D'Aurelle, Montpellier, France
Limentani, S.A.;  Carolinas Hematology-Oncology Associates, Charlotte, NC
JERUSALEM, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Lakshmaiah, K;  Kidway Memorial Institute of Oncology, Bangalore, India
Roche, H.H.;  Institut Claudius Regaud, Toulouse, France
Sanchez-Rovira, P;  Complejo Hospitaliaro de Jaén, Jaén, Spain
Pienkowski, T;  Center for Oncology, Klinika Nowotworow, Warszawa, Poland
Segui-Palmer, M.A.;  Corporacio Sanitaria Parc Tauli, Sabadell, Spain
Li, A;  Department of Biostatistics and Epidemiology, Amgen Inc., Thousand Oaks, CA
Sun, Y;  Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA
Pickett-Gies, C.A.;  Oncology Clinical Development, Amgen Inc., Thousand Oaks, CA
Wildiers, H;  Department of General Medical Oncology, Multidisciplinary Breast Centre, Leuven, Belgium
More authors (9 more) Less
Language :
English
Title :
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
Publication date :
2011
Event name :
2011 ASCO Annual Meeting
Event organizer :
ASCO
Event place :
Chicago, United States
Event date :
June 3-6 2011
Audience :
International
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
Volume :
29
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 15 October 2013

Statistics

Number of views
65 (4 by ULiège)
Number of downloads
1 (1 by ULiège)
More statistics

Bibliography

Similar publications


Contact ORBi